How much revenue does Livzon Pharmaceutical make?

Livzon Pharmaceutical reported 12.02 billion CNY in revenue for fiscal year 2025, up 1.8% from 11.81 billion CNY in fiscal year 2024. In Q1 2026 revenue was 2.87 billion CNY.

Where does Livzon Pharmaceutical make most of its revenue?

China: 84% of revenue by region in fiscal year 2025, followed by Overseas (16%).

What companies are similar to Livzon Pharmaceutical?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (688336.SS), Humanwell Healthcare (Group) Co.,Ltd. (600079.SS), Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ), Zhejiang Huahai Pharmaceutical Co., Ltd. (600521.SS).

Livzon Pharmaceutical Group Inc. (000513.SZ) Stock

About Livzon Pharmaceutical Group Inc.

Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ila...

At a glance

Livzon Pharmaceutical reported revenue of 12.02 billion CNY for fiscal year 2025, up 1.8% from fiscal year 2024, and net income of 2.02 billion CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 2.87 billion CNY, down 9.7% from a year before. China was its largest region in fiscal year 2025, with 84% of revenue.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.